The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Svechnikova E.V.

Medical Institute of Continuing Education of Rosbiotech;
Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation

Zhufina S.E.

Polyclinic №1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia, 119002

An odious combination

Authors:

Svechnikova E.V., Zhufina S.E.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(4): 26‑33

Read: 233 times

Buy for 300₽
Contact the author
Table of contents

To cite this article:

Svechnikova EV, Zhufina SE. An odious combination. Non Nocere. New Therapeutic Journal. 2025;(4):26‑33. (In Russ.)

 
 
ЭндоКард
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

A clinical case of latent tuberculosis infection detected against the background of biological therapy of psoriasis with an IL-17 inhibitor.

Authors:

Svechnikova E.V.

Medical Institute of Continuing Education of Rosbiotech;
Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation

Zhufina S.E.

Polyclinic №1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia, 119002

Close metadata

References:

  1. Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin Arthritis Rheum. 2023 Apr;59:152165. https://doi.org/10.1016/j.semarthrit.2023.152165
  2. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021 Aug 1;157(8):940-946.  https://doi.org/10.1001/jamadermatol.2021.2007
  3. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. https://doi.org/10.3390/ijms20061475
  4. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377-390.  https://doi.org/10.1016/j.jaad.2016.07.064
  5. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021 May 13;184(10):2537-2564. https://doi.org/10.1016/j.cell.2021.04.015
  6. Mrowietz U, Lauffer F, Sondermann W, Gerdes S, Sewerin P. Psoriasis as a Systemic Disease. Dtsch Arztebl Int. 2024 Jul 12;121(14):467-472.  https://doi.org/10.3238/arztebl.m2024.0064
  7. Hagenström K, Müller K, Garbe C, Augustin M. Prevalence of psoriasis and psoriatic arthritis in Germany – analysis of claims data. J Dtsch Dermatol Ges. 2024 Jan;22(1):45-54.  https://doi.org/10.1111/ddg.15269
  8. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011 Aug;270(2):147-157.  https://doi.org/10.1111/j.1365-2796.2010.02310.x
  9. Russian Society of Dermatovenerologists and Cosmetologists. Clinical recommendations. Psoriasis. Year of approval: 2023. Date of access: 20.03.2025. https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdf
  10. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021 Apr 3;397(10281):1301-1315. https://doi.org/10.1016/S0140-6736(20)32549-6
  11. Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: Effectors and targets in psoriasis – A breakthrough in understanding and treatment. J Exp Med. 2020 Jan 6;217(1): e20191397. https://doi.org/10.1084/jem.20191397
  12. Puig L, Costanzo A, Muñoz-Elías EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022 May;186(5):773-781.  https://doi.org/10.1111/bjd.20963
  13. Kocaaga A, Kocaaga M. Psoriasis: An Immunogenetic Perspective. Glob Med Genet. 2022 Jun 13;9(2):82-89.  https://doi.org/10.1055/s-0042-1743259
  14. Kuiper JJ, Prinz JC, Stratikos E, et al. EULAR study group on ‘MHC–I-opathy’: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis. 2023 Jul;82(7):887-896.  https://doi.org/10.1136/ard-2022-222852
  15. Andrees V, Wolf S, Augustin M, Mohr N, Augustin J. Regional variations and prevalence of psoriasis in Germany from 2010 to 2017: a cross-sectional, spatio-epidemiological study on ambulatory claims data. BMJ Open. 2021 Nov 16;11(11): e047806. https://doi.org/10.1136/bmjopen-2020-047806
  16. Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317.  https://doi.org/10.1111/jdv.16926
  17. Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis – time for a paradigm change. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):824-834.  https://doi.org/10.1111/jdv.16866
  18. Torres T, Chiricozzi A, Puig L, et al. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. Am J Clin Dermatol. 2024 Mar;25(2):333-342.  https://doi.org/10.1007/s40257-024-00845-4
  19. MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets – 2017. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):263-266.  https://doi.org/10.15585/mmwr.mm6811a3
  20. Robert M, Miossec P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol Immunol. 2021 Jul;18(7):1644-1651. https://doi.org/10.1038/s41423-021-00694-9
  21. LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis. 2017 Oct;17(10):e327–e333. https://doi.org/10.1016/S1473-3099(17)30248-7
  22. Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017 Apr 14;3(3):230-232.  https://doi.org/10.1016/j.jdcr.2017.02.001
  23. Snast I, Bercovici E, Solomon-Cohen E, et al. Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review. Am J Clin Dermatol. 2019 Aug;20(4):483-491.  https://doi.org/10.1007/s40257-019-00432-y
  24. Singh S, Maniakis-Grivas G, Singh UK, et al. Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis. J Pathol. 2018 Mar;244(3):311-322.  https://doi.org/10.1002/path.5013
  25. Ardain A, Domingo-Gonzalez R, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019 Jun;570(7762):528-532.  https://doi.org/10.1038/s41586-019-1276-2
  26. Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf. 2020 Apr;19(4):395-402.  https://doi.org/10.1080/14740338.2020.1736034
  27. Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis. Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):23-28.  https://doi.org/10.1159/000501989
  28. Megna M, Patruno C, Bongiorno MR, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat. 2022 Aug;33(5):2629-2633. https://doi.org/10.1080/09546634.2022.2062280
  29. Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol. 2020 Nov;83(5):1436-1439. https://doi.org/10.1016/j.jaad.2020.06.012
  30. Manzanares N, Vilarrasa E, López A, et al. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e26–e28.  https://doi.org/10.1111/jdv.19406
  31. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111.  https://doi.org/10.1186/s13075-019-1882-2
  32. Leonardi C, Reich K, Foley P, et al. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447.  https://doi.org/10.1007/s13555-020-00367-x
  33. Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018 Sep;179(3):615-622.  https://doi.org/10.1111/bjd.16724
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.